Lupin launches generic version of Lidex Ointment

Lupin's Fluocinonide Ointment USP, 0.05%, is the generic version of County Line Pharmaceuticals LLC's Lidex Ointment 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Mumbai: Pharma major Lupin Limited (Lupin) announced the launch of Fluocinonide Ointment USP, 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Fluocinonide Ointment USP, 0.05%, is the generic version of County Line Pharmaceuticals LLC's Lidex Ointment 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Lidex Ointment is used to treat a variety of skin conditions(e.g., eczema, dermatitis, allergies, rash). Fluocinonide reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a strong corticosteroid.

Fluocinonide Ointment USP, 0.05% (RLD: Lidex) had annual sales of approximately USD 15 million in the U.S (IQVIA MAT January 2019)

Headquartered in Mumbai, Lupin develops and delivers a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a position in the Anti-TB segment.

Also Read: Lupin gets USFDA nod to Sildenafil tablets to treat erectile dysfunction